Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Rushnet Inc RSHN

RushNet, Inc. operates under the name HeliosDX. HeliosDX is a national clinical reference laboratory offering high-complexity urine drug testing (UDT), behavioral drug testing, allergy droplet cards, oral fluids, and infectious disease (PCR). The Company provides management services and insurance billing services principally to clinical reference laboratories. It provides PGX testing through Leo Partners. It provides oral fluid toxicology testing for a range of drugs. The Quantisal Collection Procedure makes taking the sample quick and easy. HeliosDX also offers a preliminary 10-panel plus adulteration detection screen, as well as confirmation testing via its comprehensive toxicology panel. Its subsidiaries include Chattahoochee Physicians Laboratory Services, LLC; doing business as HeliosDx and Grandeza Healthcare Consultants, LLC.


PINL:RSHN - Post by User

Bullboard Posts
Next >>
Post by AveragePennyon Aug 17, 2021 12:43pm
88 Views
Post# 33717350

$RSHN Pursuit of TSX-V Listing

$RSHN Pursuit of TSX-V Listinghttps://www.accesswire.com/660135/heliosdx-announces-pursuit-of-tsx-v-listing-and-roadmap-update

The benefits of the listing we will be pursuing, if successful, should allow heliosDX to:

  • Provide additional liquidity to be used towards funding of future acquisitions and growth;
  • Enhances heliosDX ability to reach our future target of $50 million in annual revenue by EOY 2023;
  • Continued growth and exposure in the public sector in the U.S., Canadian and, in due course, world markets; and
  • We also believe that increased liquidity will follow assuming (as we do) that heliosDX is accepted and listed on TSX-V.
Bullboard Posts
Next >>